Although, a 2013 study that increased CTLA-4 activity using abatacept in APOE 3-leiden mice found a reduction in the severity of atherosclerosis through a dramatic 78.1% decrease in arterial thickening (161), thus offering a different avenue for ICI therapy in atherosclerosis treatment. The gene discussed is CTLA4; the disease is atherosclerosis.